FDA qualifies PathAI’s AIM-NASH for MASH trial histology

FDA qualified PathAI’s AIM-NASH, called AIM-MASH AI Assist by the company, for a defined use in scoring liver histology in MASH clinical trials. Pathologists retain final interpretation; qualification of the development tool is distinct from general diagnostic authorization or drug approval.